<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction Schema extraction-schema-2 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extraction Schema Details for extraction-schema-2</h1>

        <div class="section">
            <h2>Extraction Schema (General Information)</h2>
            <div class="info-section">
                <p><strong>Schema ID:</strong> extraction-schema-2</p>
                <p><strong>Extraction Query:</strong> Extract any mentions of studies comparing neoadjuvant-adjuvant immunotherapy to adjuvant only immunotherapy in melanoma, including clinical outcomes, mechanistic explanations, and any reported reasons for differences in efficacy.</p>
            </div>
        </div>

        <div class="section">
            <h2>Extraction Schema (Details)</h2>
            <table>
                <thead>
                    <tr>
                        <th style="width: 20%;">Field Name</th>
                        <th style="width: 15%;">Type</th>
                        <th style="width: 65%;">Description</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>study_type</strong></td>
                        <td>str</td>
                        <td>Type of study (e.g. clinical trial, preclinical study, retrospective analysis, review, meta-analysis).</td>
                    </tr>
                    <tr>
                        <td><strong>patient_population</strong></td>
                        <td>str</td>
                        <td>Description of the patient population studied, including melanoma stage and relevant inclusion criteria.</td>
                    </tr>
                    <tr>
                        <td><strong>immunotherapy_regimen</strong></td>
                        <td>str</td>
                        <td>Details of the immunotherapy regimens used, including agents, dosing, timing (neoadjuvant, adjuvant, both), and duration.</td>
                    </tr>
                    <tr>
                        <td><strong>outcomes_measured</strong></td>
                        <td>str</td>
                        <td>Clinical outcomes measured (e.g. overall survival, disease-free survival, recurrence rate, pathological complete response, event-free survival, immune-related adverse events).</td>
                    </tr>
                    <tr>
                        <td><strong>comparative_results</strong></td>
                        <td>str</td>
                        <td>Summary of comparative results between neoadjuvant-adjuvant and adjuvant only immunotherapy (e.g. hazard ratios, response rates, statistical significance, effect sizes).</td>
                    </tr>
                    <tr>
                        <td><strong>mechanistic_findings</strong></td>
                        <td>str</td>
                        <td>Mechanistic or biological findings explaining differences in outcomes (e.g. immune cell infiltration, T cell expansion, tumor microenvironment changes, antigen presentation, immune memory).</td>
                    </tr>
                    <tr>
                        <td><strong>reported_reasons_for_improvement</strong></td>
                        <td>str</td>
                        <td>Any explicit explanations or hypotheses provided in the paper for why neoadjuvant-adjuvant immunotherapy improves outcomes compared to adjuvant only.</td>
                    </tr>
                    <tr>
                        <td><strong>limitations_or_counter_evidence</strong></td>
                        <td>str</td>
                        <td>Any reported limitations, conflicting results, or counter-evidence regarding the benefit of neoadjuvant-adjuvant immunotherapy over adjuvant only.</td>
                    </tr>
                </tbody>
            </table>
        </div>

    </div>
</body>
</html>